ArticleAsian Pacific journal of cancer prevention : APJCP2025
Immunohistochemical Expression of PD-L1 and CTLA-4 in Triple Negative Breast Cancer and Their Prognostic Associations.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProgrammed Death-Ligand 1 (PD-L1) and Cytotoxic T Lymphocyte -Associated Antigen-4 (CTLA-4) are presently considered as prognostic markers and therapeutic targets in numerous human malignancies. The goal of this study was to determine whether PD-L1 and CTLA-4 might be used to predict patients' survival in Triple Negative Breast Cancer (TNBC).
methodsThis retrospective cohort study analyzed 100 primary TNBC cases that had surgical resection at the Oncology Center of Mansoura University (OCMU), Faculty of Medicine, Egypt. Clinicopathological data and survival outcomes were collected, and immunohistochemistry (IHC) was performed for PD-L1 and CTLA-4 expression.
resultIn 29% of TNBCs, PD-L1 was expressed. PD-L1 positivity was significantly associated with high tumor grade (P=0.007). PD-L1 did not, however, significantly associate with survival. CTLA-4 was expressed in 45% of TNBCs. CTLA-4 expression was significantly associated with lymph node metastasis (P=0.009), distant metastasis (P=0.001) and advanced TNM stage (P=0.001). In TNBC, multivariate analysis identified CTLA-4 expression as an independent prognostic predictor for both disease-free survival (P=0.002) and overall survival (P=0.003).
conclusionThe selection of patients for immunotherapy and checkpoint-blockade treatment may be guided by CTLA-4, an independent prognostic factor for the overall survival and disease-free survival of TNBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.